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ABSTRACT
Objective: The aim of this study was to identify human papillomavirus (HPV) in cervical intraep-
ithelial neoplasia (CIN) lesions and to evaluate the persistence of viralDNA after diathermic large
loop excision (DLLE) treatment.
Study Design: Biopsies from 36 patients with low- and high-grade CIN lesions were studied
before and after DLLE treatment looking for HPV sequences. DNA was extracted to perform a
radioactive polymerase chain reaction (PCR) using GP 5,6 generic primers. PCR products were
analyzed by the single-stranded conformational polymorphism (SSCP) which is a simultaneous
detection and typing method. Dot-blot hybridization with generic and type-specific biotinylated
oligonucleotide probes was applied in some cases.
Results: HPV DNA was found in all pretreatment samples, and the viral type was identified in
80% of them, HPV 16 being the most prevalent. The viral type coincided with that detected in the
first biopsy in all except one case. Seventy five percent of the patients (27 cases) were negative for
CIN at follow up, but 50% of them remained HPV DNA positive.
Conclusion: DLLE treatment was effective in removing the CIN lesion but not the HPV. This
fact points out the need to asses the presence of HPV in DNA during the follow-up, since viral
persistence has been considered a high risk factor for recurrence and/or malignant transformation.
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he notion that a sexually transmitted agent is
involved in the pathogenesis of cervical cancer
has been considered since the end of the past cen-
tury. Several epidemiological studies have strongly
supported this assumption, while molecular tech-
niques have indicated that certain human papillo-
mavirus (HPV) types are present in the majority of
cervical carcinomas, highlighting the contribution
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of these viruses to the carcinogenesis of the uterine
cervix. 1--4
Among HPV types that infect the genital tract,
types 16, 18, 31 and 33 are usually associated with
cervical carcinomas ("high-risk" types). A different
subset of HPV types, such as 6 and 11, are related
to benign cervical lesions ("low-risk" types).
Different techniques are currently available for
the treatment of cervical intraepithelial neoplasia
(CIN) lesions. These methods are either destruc-
tive or excisional, and the application generally de-
pends on the location, the severity of the lesion,
and the age of the patient,s The diathermic large
loop excision (DLLE) treatment applied to CIN
and HPV lesions is a local and ambulatory method
that, like the cone biopsy, allows histologic confir-
mation of the diagnosis. This method is more con-
servative than conization, a fact that can be very
important, especially if lesions are found in women
of reproductive age.
Persistence of viral DNA after treatment ofCIN
lesions is an issue that has not yet been fully stud-
ied, especially when high-risk HPV types like HPV
16 and 18 are present.
The presence of HPV DNA in clinical speci-
mens has been determined mainly by Southern
blot,6 dot blot,7 in situ hybridization,
8 polymerase
chain reaction (PCR),9-11 and hybrid capture sys-
tem. lz,13 The use of PCR has enhanced the sensi-
tivity of detection and has contributed to the in-
creased identification of HPV in cervical le-
sions.4,14,15
One of the most sensitive methods for detecting
minor structural alterations of DNA, including
point mutations, is single-stranded conformational
polmorphism analysis (SSCP) 16 with previous am-
plification b PCR. Single base substitutions that
produce conformational changes of denatured
DNA chains are detected as a mobility shift in
polyacrylamide gels under nondenaturing condi-
tions. This method has been recently applied to
HPV detection, providing information about the
viral tpe amplified.7
In this stud% we analyzed the presence of HPV
DNA by SSCP-PCR in different cervical lesions,
before and after DLLE treatment, and its correla-




Thirty-six patients with ages ranging from 17 to 45
years (mean, 31 years) were included in the study.
Five cases of CIN I, five of CIN II and 26 of CIN
III showing colpohistologic signs of HPV infec-
tion 18 were selected for DLLE treatment.
Inclusion Criteria for DLLE Treatment
Women with cervical condylomatous and CIN le-
sions, noted with colposcopic visualization of the
whole atypical lesion, both negative cytobrush and
endocervical curettage in CIN II to CIN III. Pa-
tients with large ectocervical lesions (more than 1/3
external), pregnant women, and those with diffi-
culties in the follow up were excluded.
Surgical and Histopathological Criteria
for DLLE
It was performed a conservative resection with
safety margins employing the therapeutic suffi-
cient criterion in the same way as in the bistoury
cone. 19
Two biopsies were taken from each patient, one
before and the other 6-12 months after therapy.
The second biopsy was taken from the DLLE site
in the areas of irregular or atypical reepithelization.
Specimens were fixed and paraffin-embedded for
histopathologic and virologic studies.
Lesion Evolution Criteria
Negative follow-up: Disappearance of the CIN
lesion or presence of minor histologic signs (dys-
trophy, dyskeratosis, hyper- and parakeratosis,
squamous metaplasia, etc.) after therapy.
Persistence: Presence of lesion of the same
grade.
Progression: Presence of a CIN lesion of a higher
grade than that found at the first histologic ex-
amination.
DNA Isolation and PCR Amplification
DNA was extracted and purified from paraffin-
embedded biopsies as previously described. 17
Specimens were tested by PCR for [3-globin gene
to confirm the presence of adequate human DNA
in the sample,e
We used PCR reactions with GP5,6 generic
primers that amplify a fragment of approximately
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140 bp from the L1 region. 14 As positive controls,
cloned DNA from HPV types 6, 11, 16, 18, 31, and
33 (kindly provided by H. zur Hausen, A. L6rincz,
and G. Orth) were included in all assays. The PCR
reactions were carried out in 10 pl of solution con-
taining 100-250 ng of DNA, 10 mM Tris HCI (pH
8.3), 50 mM KC1, 3 mM MgClz, 100 pM dATP,
dCTP and dTTP, 10 pM dCTP and 0.1pL o 3zp
dCTP 10 mCi/mL (DupontVM), 10 pmol of each
primer and 5 U of AmpliTaq (5 U/pL; Perkin
EImeffM). Forty cycles of amplifications were per-
formed in a Perkin Elmer GeneAmp 9600 thermo-
cycler, (94C, 30 sec; 45C, 30 sec; 72C, 30 see).
For dot-blot analysis, 50 pL final volume ofPCR
was performed as described above. Nonradioactive
dNTPs and MY09,11 consensus primers that gen-
erate a 450-bp fragment of the L1 region were
used.9
SSCP Analysis
Aliquots from PCR were diluted 1:25 with 0.1%
SDS and 10 mM EDTA; then 2 pL of them were
mixed with equal volumes of stop solution (95%
formamide, 20 mM EDTA, 0.05% bromophenol
blue, 0.05% xylene cyanol) and boiled for 5 min.
Another aliquot from PCR was diluted 1:25 in TE
and mixed with equal volume of blue dye in glyc-
erol. One microliter of diluted samples was loaded
on 6% polyacrylamide gels containing 10% glycerol
and run at 4W for 20 hr at room temperature. The
gels were fixed with 10% acetic acid, dried, and
autoradiographed using X-OMAT-AR KodakTM
films, with intensifying screen, at-70 C.
Dot-Blot Hybridization
Samples that could not be typified by SSCP-PCR
were reanalyzed by dot-blot hybridization. Dena-
turation and blotting of the PCR products were
performed by conventional methods,el Generic L1
probes were synthesized, and the hybridization was
performed as described previously,zz MY12, MY13,
MY14, WD74 and MY16 biotin-labeled oligonucle-
otides were applied as type-specific probes for
HPV 6, 11, 16, 18, and 33, respectively.
9
Aliquots (40 pL) resulting from PCR were de-
natured with 20 pL of IN NaOH and blotted to
Zeta probe (BioRadTM) membranes. Positive and
negative controls were included in each assay. Hy-
bridization was performed at 55 C for 3 hr. For
TABLE I. Pretreatment histology and clinical
evolution after DLLE
Negative Persistent
Histology N follow-up cases
CINI 5 4
CIN II 5 3 2
CIN III 26 20 6
Total (%) 36 (I 00) 27 (75) 9 (25)
aThree cases persisted as lower grade: two were CIN and one was
CIN
oligonucleotides MY12, 13, and 16, filters were
washed twice at 56 C for 10 min. For oligonucle-
otides MY14 and WD74, filters were washed simi-
larly but at 58 C. Positive hybridization was de-
veloped by chemoluminescence (PhotoGene
Nucleic Acid Detection System, BRLTa).
RESULTS
Negative follow up was observed in 27 cases and
persistence in nine cases (Table 1). One case of
CIN II was found to be CIN III in the posttreat-
ment sample; this observation was not considered
as a progression but rather disease that was not
detected at the first biopsy. However, in 30% of
negative follow-up cases and 88% of persisting
cases, histologic HPV signs were observed in post-
treatment biopsies.
A total of 52 colposcopically-directed biopsies of
the cervix were examined for the presence of HPV
DNA sequences. All extracted DNA was found ad-
equate for PCR assay (positive for [3-globin gene).
The SSCP- PCR analysis allowed us to establish
band patterns for each control type of HPV. The
typing was made comparing these migration pat-
terns with those observed in cervical samples (Fig.
1). All pretreatment samples were HPV positive.
Sixteen cases were found to contain HPV 16; eight
cases revealed the presence of HPV 6; two cases
showed HPV 33, and HPV types 11, 18, and 31
were found in one case each. In eight positive
cases, the HPV type could not be determined by
this method, since their patterns did not corre-
spond to any one of the standard controls. How-
ever, all of the undetermined cases hybridized with
L1 generic probe, corroborating the presence of the
virus. Two cases yielded two extra bands that sug-
gested HPV 16 and 18 mixed infections; this pos-
sibility was confirmed by dot-blot hybridization.
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Fig. I. SSCP-PCR analysis of HPV types in CIN lesions before and after DLLE treatment. Genomic DNA was isolated from
paraffin-embedded CIN biopsies and subjected to SSCP-PCR analysis using GP5,6 generic primers. PCR products were
denatured and electrophoresed on 6% nondenaturing polyacrylamide gels containing 10% glycerol, as described in the text.
Lanes and 15: undenatured double-stranded HPV DNA; lanes 2-7: cloned viral DNA corresponding to types 6, II, 16, 18,
3 I, and 33; lanes 8-14: viral types found in A, B, C, and D, DNA’s patient (the subscripts and 2 indicate samples taken before
and after treatment, respectively); lane 16: negative control (mixed reaction without DNA).
Six cases remained undetermined. Further charac-
terization of these samples was not possible due to
the limited amount of the specimen.
Fifty-five percent of posttreatmcnt samples (20
cases) remained HPV-positive; they exhibited the
same viral type found in prctrcatmcnt samples, ex-
cept in one case (HPV 6 in the first biopsy and
HPV 16 in the second). In 16 posttreatment
samples, HPV DNA was not detected; however,
eight of these biopsies exhibited persistent histo-
logic signs of viral infection.
Tables 2 and 3 show the HPV distribution in
negative follow tap and persistent cases after
DLLE treatment.
DISCUSSION
Much effort has been devoted to the early detec-
tion and prevention of cervical cancer, and differ-
ent conservative methods for the treatment of pre-
invasive lesions have been developed and exten-
sively applied. However, the persistence of HPV
infection after treatment and its relationship with
the lesion evolution has only recently become an
important area of research,e3
In the present study, we verify the efficacy of
DLLE treatment, no matter what viral type was
TABLE 2. HPV in negative follow-up cases after DLLE
Pretreatment HPV types
histology 6 16 18 31 33 UD
b
ClNl(n=4) 3c(2) I(I)
ClN II (n=3) I(I) 2(I)
ClN III (n=20) 5(2) II (S) I(0) I(0) I(I) I(I)
aPre- and posttreatment DNA HPV positive cases. The difference be-
tween both values corresponds to negative HPV cases after treatment.
bUndetermined cases by SSCP-PCR and dot-blot hybridization.
tin one case, HPV 6 was detected in the first biopsy and HPV 16 in the
second.
involved. A favorable clinical evolution and a high
rate of histologic remission was observed in most of
the patients during follow-up.
We employed a sensitive SSCP-PCR assay to
detect and type HPV DNA and to evaluate the
persistence of the virus after DLLE treatment.
This methodology allowed us to identify, in a
single reaction, several anogenital HPV types, since
the pattern obtained for each one was very specific
and highly reproducible. This assay let us avoid, in
most cases, later restriction enzyme digestion and/
or hybridization.
Some atypical patterns were observed in a lim-
ited number of cases that could correspond either
to mixed infections, variants of known types, or
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TABLE 3. HPV in persistent cases after DLLE
Pretreatment HPV types
histology 6 16 18 31 33 UD
b
CINI(n=I) I(0)
CINIl(n=2) I(I) I(I) I(I)
CIN III (n 6) 4 (2) I(I) 2 (2)
aPre- and posttreatment DNA HPV positive cases. The difference be-
tween both values corresponds to negative HPV cases after treatment.
bUndetermined cases by SSCP-PCR and dot-blot hybridization.
COne case showed HPV 16 + 18 mixed infection.
different types other than those used as controls.
This approach allowed us to successfully deter-
mine the viral type in the majority of the samples
(78%). The fact that HPV 16 was the most preva-
lent type in CIN III lesions corroborated the strong
association between this high-risk type and severe
lesions.
Using dot-blot hybridization, we were able to
identify a mixed infection associated with an un-
determined SSCP-PCR pattern. The method al-
lowed us to confirm and extend the results ob-
tained with the SSCP-PCR assay. The few cases
that remained undetermined by dot-blot hybridiza-
tion were CIN III, supporting the necessity of
identifying oncogenic HPV types other than 16, 18,
31, and 33.
In about half of negative SSCP-PCR cases, his-
tologic HPV signs remained. This fact could indi-
cate that structural modifications of tissues, related
to HPV infection, may persist even when the viral
DNA is not found. Another possibility is that koi-
locytosis or cytophatic effects were the possible
consequence of other infections. We could not rule
out problems associated with the sensitivity of the
methodology used, although SSCP-PCR is able to
detect less than 10 copies of HPV.
Detection of the same viral type of HPV DNA
during the follow up is likely to reflect the persis-
tence of the infection, but the possibility of rein-
fection with the same virus exists. Development
and validation of HPV testing strategies, including
the assessment of viral load, would appear increas-
ingly relevant.
Persistence of HPV DNA has been associated
with several factors including presence of high-risk
types, viral load, age, number of sexual partners,
sex hormone regulation, and host immunity,z4 In
this study, persistence ofHPV DNA was associated
with the presence of HPV 16 as well as HPV 6.
The DLLE treatment proved effective in the
eradication of CIN lesions, but seems to fail in
eliminating the viral infection. In spite of the nega-
tive follow up observed, in half of treated patients,
HPV DNA was demonstrated. Several epidemio-
logical studies have indicated that persistently in-
fected women with oncogenic HPV types are more
likely to develop cervical neoplastic lesions,zs In
our treated patients, viral persistence with previous
history of severe cervical disease would be consid-
ered a greater risk factor of relapse.
These findings highlight the importance of per-
forming follow-up studies over prolonged periods
due to the possibility of recurrence and/or malig-
nant conversion of premalignant lesions. Our re-
suits emphasize the importance of the virological
test to complement the clinical study, improving
the diagnostic accuracy and efficiency.
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